Detalles de la búsqueda
1.
Comprehensive Analysis of Hypermutation in Human Cancer.
Cell
; 171(5): 1042-1056.e10, 2017 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29056344
2.
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Oncologist
; 28(8): 691-698, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37354528
3.
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Oncologist
; 27(9): 732-739, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598202
4.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919526
5.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Oncologist
; 25(1): e147-e159, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578273
6.
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.
Oncologist
; 24(2): 219-228, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30108156
7.
A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
J Virol
; 92(14)2018 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29743355
8.
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Cancer
; 124(7): 1358-1373, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29338072
9.
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.
Antimicrob Agents Chemother
; 61(8)2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28584151
10.
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
Oncologist
; 22(12): 1444-1450, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29079636
11.
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Oncologist
; 22(12): 1478-1490, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28912153
12.
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
J Am Acad Dermatol
; 80(6): 1780-1782, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30576761
13.
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages.
Diagnostics (Basel)
; 14(9)2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38732326
14.
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
J Immunother Cancer
; 11(11)2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38035725
15.
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Nat Med
; 29(4): 859-868, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36928816
16.
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
JCO Precis Oncol
; 7: e2300093, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37769224
17.
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.
NPJ Precis Oncol
; 6(1): 44, 2022 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35739333
18.
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Nat Med
; 28(5): 939-945, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35422531
19.
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
NPJ Precis Oncol
; 6(1): 91, 2022 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36494601
20.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Nat Med
; 28(9): 1831-1839, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35995953